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a b s t r a c t
Hematopoietic progenitor cells from peripheral blood (HPCPB) are commonly used for autol-
ogous and allogenic transplants in patients with most various onco-hematological diseases,
and despite the utilization of sterile techniques during collection and processing of these
products, bacterial contamination can occur. This study aimed to investigate the micro-
bial contamination of HPCPB products. Microbial cultures of 837 HPCPB products between
the year 2000 and 2009 were retrospectively analyzed to determine the incidence of culture
positivity and identify the main organisms that cause contamination. The microbiologi-
cal studies were performed with an automated system (BacT/Alert® bioMérieux Corporate).
Thirty-six (4.3%) of 837 microbial cultures were contaminated. Coagulase-negative Staphy-
lococcus was the most frequent bacteria isolated from HPCPB products (20 [56%] of the 36
positive microbial cultures). Considering the 36 contaminated samples, 22 HPCPB products
were infused and 14 discarded. Pre- and post-infusion antibiotic therapy of the patients
transfused with contaminated products was established based on the isolated microor-ganism and its antibiogram. Microbial contamination rate of HPCPB products was low.
Clinically signiﬁcant outcomes after infusion of contaminated HPCPB products were not
observed.
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traditional source for obtaining HPCPB, collected by multi-
ple punctures and aspirations of the posterior iliac crests.
The aspirated material contains red blood cells, leukocytes,of Infectious Diseases, Rua Ramiro Barcelos, 2350, Porto Alegre,
platelets, mast cells, plasma, and pluripotent hematopoietic
progenitor cells. In recent years, the collection of HPCPB via
apheresis has been increasingly used. The combination of
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Table 1 – Management considerations of HPCPB products with positive microbial cultures.
Administer the product Discard the product
Slow growing organism* Rapidly growing organism
Skin or environmental contaminant Enteric or pathogenic organism
Donor or patient is not available for recollection Product can easily be replaced
New product requires remobilization or central line placement Patient can tolerate delay and recollection
Product contains majority of total cell dose Product contains small percentage of total cell dose
the 837 collected samples (4.3%) yielded positive cultures for
bacteria. Fig. 1 presents the annual contamination rate of the
HPCPB products from 2000 to 2009. As shown in Fig. 2, the
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∗ Culture positivity beyond 30hours of incubation.
high doses of chemotherapy with subsequent transplantation
of these cells constitutes the standard treatment for many
onco-hematological diseases.
Obtaining, processing, storing and transplantation of
HPCPB involve many steps, which are normally performed
in different environments and may result in microbial con-
tamination. In fact, HPCPB manipulation during processing
and pre- and post-cryopreservation are important sources of
bacterial contamination of these cells.1 The donor may be
the source of microbial contamination of HPCPB. Donors with
asymptomatic bacteremia or who are recovering from a bac-
terial infection may develop episodes of transient bacteremia,
which can lead to product contamination. In addition, HPCPB
collected by apheresis often requires the insertion of central
venous catheters (CVC). Infections associated with CVCs are
an important source of transient bacteremia and a possible
cause of HPCPB contamination.2
Thus, in order to ensure a ﬁnal product appropriate for
transplant, it is essential to adhere to a quality control policy.
Such controls should include CD34+cell count, cell viability
assessment, and microbiological monitoring.3
The main objective of this study was to investigate the
incidence of positive microbial cultures for HPCPB products
from donors attending a tertiary care hospital in the period
from 2000 to 2009. In parallel, the major bacteria contaminat-
ing HPCPB products and the pre- and post-infusion antibiotic
therapy for the contaminated cells were also described. In
addition, the blood culture results after thawing the bag con-
taining HPCPB, which were infused or discarded according to
medical decision, were also analyzed (Table 1).
Material and methods
Microbial cultures of 837 HPCPB products of donors attend-
ing a tertiary care hospital located in southern Brazil from
2000 to 2009 were retrospectively analyzed to determine the
incidence of microbial culture positivity and identiﬁcation of
the main organisms causing contamination. In addition, the
charts of the donors with positive HPCPB microbial cultures
were reviewed.
For the sterility control of the HPCPB products, after the
cryopreservation process and before freezing, 3mL samples
of the product were inoculated in pediatric blood culture bot-
tles with 20mL of activated charcoal (BacT/Alert® bioMérieux
Corporate–Durham,USA). In addition, after bloodbag thawing,
samples were collected for microbial cultures at the moment
of the infusion. Such action serves to verify a possible con-
tamination at the time ofwater-bath defrosting. Culturesweresent to the microbiology department, where they were incu-
bated for ﬁve days. When positive, microscopy and bacterial
isolationwere performed and identiﬁed through standard bio-
chemical tests.
Data were organized and analyzed using the Microsoft
Excel 2007® software, according to the distribution of fre-
quency.
Microbiological surveys were performed with automated
BacT/Alert® at 36 ◦C. The products were added into a class I
laminar-ﬂow cabinet with HEPA ﬁlters.
The study was approved by the local ethics committee,
which is accredited by the National Committee of Ethics in
Research of the National Health Department and the Ofﬁce
for Human Research Protection (OHRP) of the United States.
Results
A total of 837 HPCPB collections and microbial cultures
were performed at the hemotherapy section from 2000 to
2009. The average volume drawn and time for collection
and processing were 255mL and 206minutes respectively.
The underlying diseases and the main characteristics of
the patients that received HPCPB products are presented in
Table 2. The main underlying diseases included multiple
myeloma (n=314), followed by Hodgkin lymphoma (n=143),
non-Hodgkin lymphoma (n=132), acute myeloid leukemia
(n=63), neuroblastoma (n=52), Wilms tumor (n=28), medu-
loblastoma (n=23), and Ewing sarcoma (n=16).Thirty-six ofFig. 1 – Annual rate of contamination in samples collected
in the period from 2000 to 2009. Distribution of the 36
contaminated samples of total 837 made in this period.
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Table 2 – Proﬁle of underlying diseases and HPCPB collections performed at the Hemotherapy Section from 2000-2009.
Underlying disease n (collections) Age (average) Gender
M F
Amiloydosis 3 58 1 2
Erythroid series aplasia 1 6 – 1
Pleuropulmonary blastoma 3 4 – 3
CNS germinoma 1 13 1 –
Immunocytoma 1 40 – 1
Acute lymphoblastic leukemia 2 17 – 2
Acute lymphoide leukemia 5 20 4 1
Acute myeloid leukemia 63 31 47 16
Chronic myeloid leukemia 2 42 – 2
T-cell lymphoma 1 32 – 1
Hodgkin lymphoma 143 26 59 84
Mantle-cell lymphoma 2 57 2 –
B-cell granulocytic lymphoma 3 41 3 –
T cell lymphoblastic lymphoma 1 34 1 –
Non-Hodgkin lymphoma 132 43 82 50
Peripheral T lymphoma 2 33 – 2
Medulloblastoma 23 12 18 5
Myelophibrosis 1 45 1 –
Multiple myeloma 314 54 170 144
Tumor of suprarenal gland 3 4 3 –
Thoracic malignant neoplasm 1 7 – 1
Malignant neoplasm of kidney and renal pelvis 2 9 2 –
Neuroblastoma 52 4 41 11
Pancreatoblastoma 1 15 – 1
Pineoblastoma 2 3 – 2
Retinoblastoma 6 6 4 2
Renal cell sarcoma 1 4 1 –
Ewing sarcoma 16 13 5 11
Wilms sarcoma 1 11 1 –
Poems syndrome+Castleman disease 1 50 1 –
Askin tumor 5 16 1 4
Renal cell tumor 1 5 1 –
Ewing tumor 1 11 – 1
Ovarium tumor 2 12 – 2
Endodhermal sinus tumor 4 15 2 2
Testicle tumor 3 28 3 –
Wilms tumor 28 6 12 16
Germinative tumor 4 18 4 –
7
m
S
B
c
a
F
h
pTotal 83
ost frequently isolated organism was coagulase-negative
taphylococcus (56%), followed by Staphylococcus aureus (17%),
acillus sp. (8%), coryneform Gram-positive bacilli (8%), non-
oryneform Gram-positive bacilli (6%), Enterobacter sp. (3%),
nd Citrobacter freundii (3%). Coagulase-negative Staphylococcus
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ig. 2 – Bacteria isolated in the 36 contaminated
ematopoietic progenitor cells from peripheral blood
roducts.470 367
isolates were 100% resistant to beta-lactams antibiotics
including oxacillin.
Twenty-two of the 36 HPCPB products with positive micro-
bial cultures were infused. and 14 were discarded based on
the medical staff’s decision. Considering that HPCPB prod-
ucts contamination has an impact in reducing the number
of CD34+ cells, and therefore reducing hematopoietic engraft-
ment after peripheral blood stem cell transplantation, Table 3
presents the CD34+ counts of the discarded contaminated
HPCPB collections and the remaining stock collections for each
patient.
Table 4 presents pre-infusion and post-infusion antibiotic
therapy of the patients transfused with contaminated prod-
ucts. Although nine of the 22 infusions had not received
antimicrobial therapy prior to the infusion of HPCPB products,
all of the patients received such therapy during or after the
HPCPB infusion.
Twelve (55%) of the 22 contaminated HPCPB products
presented positive microbial cultures after the freeze-thaw
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Table 3 – CD34+ count of contaminated and remaining stock HPCPB collections.*
Donor-bacteria nX106CD34/Kg (discarded collection) nX106CD34/Kg (remaining stock collections)
1- Citrobacter freundii 0.35 1.43
2- Staphylococcus coagulase neg. 0.13 0.29
3- Staphylococcus coagulase neg. 3.21 3.33
3- Staphylococcus aureus
3- Staphylococcus aureus
3- Staphylococcus aureus
3- Staphylococcus coagulase neg.
4- Staphylococcus aureus 1.67 2.56
5- Staphylococcus aureus 0.32 1.39
6- Staphylococcus coagulase neg. 3.2 7.61
7- Staphylococcus aureus 1.01 4.11
8- Coryneform Gram+ bacilli 1.33 -
8- Coryneform Gram+ bacilli
9- Staphylococcus coagulase Neg. 1.27 3.14
HPCPB, hematopoietic progenitor cells from peripheral blood.
HPCPB, hematopoietic progenitor cells from peripheral blood; M, masculine; F, feminine; CNS, central nervous system.
∗ Total of 14 discarded collections; each number represents a patient; patients 3 and 8 had more than one collection.
Table 4 – Antibiotic therapy of pre- and post-infusion of contaminated HPCPB.*
Bacterium Pre-infusion Post-infusion
1- Non-coryneform Gram+bacilli Non-administered Norﬂoxacin
2- Staphylococcus coagulase neg. Non-administered Ampicillin + cefepime
3- Bacillus sp. Ciproﬂoxacin Vancomycin+ ciproﬂoxacin
4- Staphylococcus coagulase neg. Sulfa + trimethoprim Vancomycin
5- Enterobacter sp. Norﬂoxacin+ sulfa + trimethoprim Cefepime
6- Staphylococcus coagulase neg. Non-administered Gentamicin+ cefepime
7- Staphylococcus coagulase neg. Non-administered Vancomycin+ cefepime
8- Bacillus Gram+ coryneform Ciproﬂoxacin Vancomycin+ cefepime
9- Staphylococcus coagulase neg. Clindamycin Cefepime+amikacina
10- Staphylococcus coagulase neg. Ciproﬂoxacin Oxacilin + cefepime
11- Staphylococcus coagulase neg. Oxacillin Vancomycin+ cefepime
12- Bacillus sp. Cefepime Amikacin
13- Bacillus sp. Non-administered Vancomycin+ cefepime
14- Staphylococcus coagulase neg. Clindamycin Clindamycin
15- Staphylococcus coagulase neg. Non-administered Oxacillin + cefepime
16- Staphylococcus coagulase neg. Clindamycin Cefepime+oxacilin
17- Staphylococcus coagulase neg. Sulfa + trimethoprim Vancomycin
17- Staphylococcus coagulase neg. Sulfa + trimethoprim Vancomycin
18- Staphylococcus coagulase neg. Non-administered Cefepime+clindamycin
19- Staphylococcus coagulase neg. Oxacillin Cefepime
20- Staphylococcus coagulase neg. Non-administered Cefepime+vancomycin
21- Non-coryneform Gram+ bacilli Non-administered Cefepime
ientsHPCPB, hematopoietic progenitor cells from peripheral blood.
∗ The above contaminated infusions were performed in different pat
process, whereas in the remaining products (45%) the cultures
were negative.
Discussion
Similar to the present results, previous studies have reported
microbial contamination rates varying from 1.6% a 4.5%.4–8
The incidence of microbial contamination of HPCPB prod-
ucts in those studies varied according to the source of the
cells. Kamble et al.5 have shown contamination in four of
the 26 collections (15%) from core blood, eight of 177 (4.5%)
from bone marrow, and 21 of 532 (3.9%) from peripheral, except nr. 17.
blood. Coagulase-negative Staphylococcus was the organism
predominantly isolated in this study, with 20 (56%) of the
36 positive microbial cultures. Most of the previous stud-
ies also identiﬁed the coagulase-negative Staphylococcus and
other bacteria that often colonize the skin and are water
contaminants.9–12 The potential contamination sources of
HPCPB products include reagents, venous access-catheters,
aseptic failure, cell processing, bag disruption, equipment
used for water-bath, incubators, and centrifuges.13–17Even though contaminated HPCPB products are often
discarded, 22 of the 36 contaminated collections were
infused. Authors have reported success achieved after the
infusion of the contaminated HPCPB products, with few
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linical consequences.9,18 In fact, contaminated HPCB prod-
cts should not be automatically discarded because, when
dministered with speciﬁc precautions, they do not have
ither adverse effects or signiﬁcant sequelae. As shown in
able 1, speciﬁc measurements should be considered when
eciding to discard or administer the product.19
CD34+ cell dose is correlated with both early engraft-
ent kinetics and late peripheral blood counts. A threshold
ffect between rapid and slow engraftment occurred at 5× 106
D34+ cells/kg. In addition, hemoglobin and platelets were
igniﬁcantly higher at 180, 360, and 540 days after transplan-
ation for those patients who received >5× 106 CD34+ cells/kg.
herefore, for autologous transplantations, a dose higher than
D34+ cell appears to be correlated with improved long-term
ematopoiesis. In this study,most of the contaminated collec-
ions presented low CD34+ cell dose. Despite contamination,
ome frozen stocks of those collections from these patients
resented high CD34+ cell dose, which could be successfully
sed in further HCPBC transplants.
Contamination of HPCPB products with clinically signif-
cant adverse outcome occurs especially with potentially
athogenic bacteria, but is rare, with an incidence of 0.3%
f notiﬁed cases.5 Klein et al.20 have reported a patient that
ied due to multi-organ-system failure, after having received
PCPB product contaminated with Burkholderia cepacia, even
hough the infusion was initiated with proper antimicro-
ial therapy. Moreover, contaminated HPCPB products with
ethicillin-resistant Staphylococcus aureus have been shown
o cause severely disseminated infection in patients.5 Inter-
stingly, bacterial contamination of those products does not
ffect the patients’ transplant kinetics. It was previously
emonstrated by Schwella et al.12 that there was no signiﬁ-
ant differences in hematopoietic recovery time, duration of
ever, and number of days of antimicrobial administration
n patients who had received contaminated HPCPB products
hen compared with those who had received products free
f contamination.12 In fact, previous studies have shown that
ost patients successfully receive an HPCPB product with
rophylactic antibiotic therapy before infusion of the contam-
nated product based on the isolated organism, sensitivity to
ntimicrobial agents and urgency for the transplant.20 This
ecisionvaries indifferent centers. For instance, Kamble et al.5
ave reported that prophylaxis is unnecessary, because most
f the contaminations are caused by non-pathogenic bacte-
ia and their infusions rarely cause bacteremia or septicemia.
nterestingly, some patients infused with collections con-
aminated with coagulase-negative Staphylococcus that were
reated with inappropriate prophylactic antibiotics such as
xacillin and ciproﬂoxacin did not present any unfavorable
utcome.
In the present study approximately 50% of the HPCPB
ollections were found to persist contaminated after the
reeze-thaw process. One of the reasons for this ﬁnding could
e the contamination of HPCPB products with a low number
f colony forming units of bacteria. In addition, cryopro-
ectors used in HPCPB products, such as the organosulfur
ompound dimethyl sulfoxide (DMSO), have potent bacte-
icidal properties against Gram-positive and Gram-negative
acteria.19 Kipp et al.6 have shown that the CFUs of different
acteria diminished after the cryopreservation process. For2;16(4):345–350 349
instance, the CFU of Staphylococcus epidermidis, decreased
approximately 13.7% after addition of DMSO. Moreover, the
presence of active phagocytic cells in the frozen products
could additionally eliminate existing bacteria.6 On the other
hand, Gram-positive bacteria such as Staphylococcus sp.
are known to survive after the cryopreservation process.5
Different studies have shown conﬂicting results regarding
the survival of coagulase-negative Staphylococcus after the
cryopreservation process.9,12,16
Data have shown that aseptic conditions impact bacterial
contamination in areas where HPCPB products are handled
and processed. There is a 5.2% decrease in HPCPB products
contamination at a clean bench compared with 0.8% decrease
at a bench in laboratory implementing good manufacturing
practiceswith certiﬁed conditions.11 Thus, quality control and
good practices of handling and conservation of reagents and
equipment used in cell cryopreservation are essential to pro-
vide safer products for patients, with reduction of the probable
contamination sources.21
In summary, our study has shown that the contamination
rate of HPCPB products is overall low and it is usually caused
by the normal skin microbiota, which could survive the cryop-
reservation process. No clinically signiﬁcant outcomes were
observed in patients transfused with contaminated HPCPB
products. Continuous monitoring of HPCPB products is essen-
tial to assure the success of the transplantation.
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